Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (236)	2/26/2002 10:02:02 AM
From: nigel bates	Read Replies (1) of 625

Seems like a poor use of words to me. Apparently Xoma chose the words to put collaborators and other phage library companies on notice about possible risk of using phage technology from companies that have not perfected their own license agreements with XOMA?... If you'd read the full PR, you would have noticed this at the bottom - SOURCE: MorphoSys AG I may be wrong, but I suspect that Xoma has tried to negotiate a similar licence with CAT, and failed to do so. I don't think Morphosys would have been their first choice for free access ("XOMA will receive the right to use the HuCAL® GOLD antibody library for target research and discovery purposes for five years") to a phage library. Again, from the PR - ``Our license to the XOMA technology underscores the respect we attach to intellectual property rights as they apply to our technologies and speaks to our commitment to becoming a product company. Additionally, we are very pleased that XOMA has chosen the HuCAL® GOLD technology over other antibody phage display libraries for their target discovery and therapeutic antibody applications..." Morphosys is involved in litigation with CAT. The above seems to me to be a bit of needle. nig

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next